A new column-based purification system and approach are described for rapid separation and purification of the alpha-emitting therapeutic radioisotope .sup.211At from dissolved cyclotron targets that provide highly reproducible product results with excellent .sup.211At species distributions and high antibody labeling yields compared with prior art manual extraction results of the prior art that can be expected to enable enhanced production of purified .sup.211At isotope products suitable for therapeutic medical applications such as treatment of cancer in human patients.

An elution apparatus and a detection apparatus are described. The elution apparatus includes: a sample trap for trapping a sample; and one or more pumps and/or valves to move a liquid eluent and a liquid eluate, wherein the eluate includes an extracted portion of the sample that is extracted by the eluent. The detection apparatus includes: a capillary having a low-voltage (LV) end portion to receive a sample; and a conductivity detector coupled to a high-voltage (HV) end portion of the capillary to generate signals based on conductivity of a monitored portion of the capillary in the HV end portion, wherein the conductivity detector is electrically isolated from the LV end portion.

An elution apparatus and a detection apparatus are described. The elution apparatus includes: a sample trap for trapping a sample; and one or more pumps and/or valves to move a liquid eluent and a liquid eluate, wherein the eluate includes an extracted portion of the sample that is extracted by the eluent. The detection apparatus includes: a capillary having a low-voltage (LV) end portion to receive a sample; and a conductivity detector coupled to a high-voltage (HV) end portion of the capillary to generate signals based on conductivity of a monitored portion of the capillary in the HV end portion, wherein the conductivity detector is electrically isolated from the LV end portion.

The present disclosure generally relates to methods for separating Δ.sup.8-THC, Δ.sup.9-THC, and related enantiomers using CO.sub.2-based chromatography.

The present invention relates to a process for the preparation of Linaclotide by oxidizing linear Linaclotide of formula (II) using combination of air and oxidizing agent followed by purification using RP-HPLC.

The invention relates to a method for determining the presence of at least one distinct polypeptide in a biological sample comprising contacting the biological sample with a hydrolyzing agent, wherein the hydrolyzing agent is capable of hydrolyzing the distinct polypeptide in a sequence-specific manner such that at least one distinct peptide having a predetermined peptide measured accurate mass would result if the at least one distinct polypeptide were present in the biological sample, to obtain a hydrolyzed sample; bringing the hydrolyzed sample in contact with a substrate comprising at least one immobilized binding partner, wherein the at least one immobilized binding partner is capable of specifically binding the distinct peptide; removing the hydrolyzed sample from the substrate in a manner such that the distinct peptide would remain bound to the immobilized binding partner; contacting the substrate with an elution solution, wherein the distinct peptide would dissociate from the immobilized binding partner into the elution solution; subjecting a portion of the elution solution to liquid chromatography to segregate a plurality of molecules in the portion of the elution solution to obtain sorted molecules; determining the measured accurate mass of at least one sorted molecule present in the elution solution; and determining the presence of the at least one distinct polypeptide in the biological sample when a measured accurate mass of at least one molecule is substantially equal to the predetermined peptide measured accurate mass.

Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.

High resolution affinity chromatography combining affinity resolving and affinity capture processes using a single chromatography matrix results in improved resolution between closely related molecular species and significantly enhances overall product yield for large scale commercial production of heterodimeric proteins such as bispecific antibodies. Moreover, tankage and equipment requirements are reduced via the ability to reduce salt concentration, while increasing product purity and concentration, without the need for dilution, ultrafiltration or diafiltration.

Provided herein are methods for purification of RNA from a sample. The methods include obtaining a first sample including double stranded RNA in a loading buffer, loading the sample onto a ceramic hydroxyapatite column, washing the column with wash buffer, and eluting the column with an elution buffer to create an eluate.

The subject technology is directed to a CO.sub.2-based chromatography system and method for rapid determination of the levels and/or the presence or absence of steroids or steroid derivatives in a sample.